Gene Expression News and Research

RSS

Gene Expression is the process by which a gene gets turned on in a cell to make RNA and proteins. Gene expression may be measured by looking at the RNA, or the protein made from the RNA, or what the protein does in a cell.

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

Idera Pharmaceuticals, Inc. announced today that it is presenting preclinical data from a study evaluating the mechanism of action of one of its Toll-like receptor (TLR) 7 and TLR9 antagonist candidates in a model of hyperlipidemia.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today that it will present new data at the inaugural CPRIT Innovations in Cancer Prevention and Research Conference, November 17-19, 2010 in Austin, TX.

17 Nov 2010

WaferGen third quarter revenue increases to $633,000

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today reported financial results for the three and nine months ended September 30, 2010.

15 Nov 2010

Research on E.Coli bacteria could help develop new vaccine for urinary tract infection

Urinary tract infections are a painful, recurring problem for millions of women. They are also getting more dangerous as bacteria develop resistance to the most common treatments.

15 Nov 2010

Researchers study Rett neurons in a Petri dish

A collaborative effort between researchers at the Salk Institute for Biological Studies and the University of California, San Diego, successfully used human induced pluripotent stem (iPS) cells derived from patients with Rett syndrome to replicate autism in the lab and study the molecular pathogenesis of the disease.

12 Nov 2010

Novel mechanism regulating circadian rhythm identified

Scientists from the Florida campus of The Scripps Research Institute have identified for the first time a novel mechanism that regulates circadian rhythm, the master clock that controls the body's natural 24-hour physiological cycle. These new findings could provide a new target not only for jet lag, shift work, and sleep disturbances, but also for disorders that result from circadian rhythm disruption, including diabetes and obesity as well as some types of cancer.

11 Nov 2010

USPTO issues Notice of Allowance to Asuragen’s mir-205 for lung cancer diagnosis

Asuragen, Inc., a leader in the development of molecular diagnostics, announced today that it had received a Notice of Allowance from the United States Patent and Trademark Office for claims related to the use of mir-205 as a diagnostic in lung cancer.

11 Nov 2010

Depression associated with molecular-level disturbance in body's 24-hour clock

Depression appears to be associated with a molecular-level disturbance in the body's 24-hour clock, new research suggests.

11 Nov 2010

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Examining the blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage, say researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center.

9 Nov 2010

Chemotherapy for breast cancer does more harm than good

A fundamental principle of medicine is: "first, do no harm." However, for doctors who treat breast cancer, this is easier said than done. Every year, almost 22,000 Canadian women are diagnosed with breast cancer - their treatment usually involves surgery to remove a tumour and then chemotherapy to reduce the risk of cancer returning.

9 Nov 2010

Study discovers role of Vav1 oncogene in several cancers

Researchers at the Hebrew University of Jerusalem have discovered that Vav1 - an oncogene (cancer-causing gene) found in recent years to be one of the factors in tumorous tissue growth -- plays a wider role in several types of cancer than had previously been thought. The discovery has implications for further concentration on targeting this gene in cancer research.

9 Nov 2010

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Athersys, Inc. announced today that the U.S. Food and Drug Administration (FDA) has authorized commencement of a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem, Athersys' allogeneic investigational cell therapy product, for the potential treatment of ulcerative colitis.

8 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Researchers identify gene linked to melanoma metastasis

Researchers at Washington University School of Medicine in St. Louis have identified a gene linked to the spread of eye melanoma.

8 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

Agilent announces solution for exon analysis based on SurePrint G3 Exon Microarrays

Agilent Technologies Inc. today announced a solution for exon analysis based on SurePrint G3 Exon Microarrays. The solution provides a major expansion of Agilent's portfolio of gene expression reagents, microarrays and bioinformatics systems. This new system, available in mid-November, enables researchers to examine alternately expressed exons according to recently updated content, providing a global picture of RNA expression.

4 Nov 2010

Gene Expression News and Research

Further Reading

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

WaferGen third quarter revenue increases to $633,000

Research on E.Coli bacteria could help develop new vaccine for urinary tract infection

Researchers study Rett neurons in a Petri dish

Novel mechanism regulating circadian rhythm identified

USPTO issues Notice of Allowance to Asuragen’s mir-205 for lung cancer diagnosis

Depression associated with molecular-level disturbance in body's 24-hour clock

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Chemotherapy for breast cancer does more harm than good

Study discovers role of Vav1 oncogene in several cancers

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Researchers identify gene linked to melanoma metastasis

Athersys secures three Therapeutic Discovery Project grants

Agilent announces solution for exon analysis based on SurePrint G3 Exon Microarrays

Regulus receives $488,989 grant under QTDP program

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Illumina launches TruSeq sample preparation, Exome Enrichment kits for sequencing studies

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®